Core Viewpoint - VanadiumCorp Resource Inc. has successfully closed a non-brokered private placement financing, raising a total of $396,099.99 to support its working capital and corporate purposes [1][4]. Financing Details - The company issued 3,600,909 Units, with each Unit comprising 1 common share and 1 common share purchase warrant, exercisable at $0.15 for 2 years [2]. - Two insiders subscribed for 960,000 Units, totaling $105,600, qualifying as a related party transaction under MI 61-101 [3]. Company Overview - VanadiumCorp is a Canadian critical metals exploration company, owning 100% of two strategic properties in Quebec: The Iron T and the flagship Lac Doré property [6]. - The company is focused on innovative technologies to extract vanadium-titanium and potentially high-grade iron from its vanadiferous titanomagnetite projects, aiming for a stable long-term supply of critical metal deposits [6]. - An initial electrolyte facility in Val-des-Sources, Quebec, will evaluate output quality and facilitate initial electrolyte production, with plans to expand production for the international market, particularly for Vanadium Flow Batteries [6].

Core Insights - The article discusses the recent developments in the industry and their implications for companies involved [1] Group 1 - The industry is experiencing significant changes due to regulatory updates and market dynamics [1] - Companies are adapting their strategies to align with new consumer preferences and technological advancements [1] - Financial performance metrics indicate a shift in profitability among key players, with some reporting increases while others face declines [1] Group 2 - Investment opportunities are emerging in sectors that are innovating rapidly, particularly in technology and sustainability [1] - Risks associated with market volatility and geopolitical factors are highlighted, affecting overall industry stability [1] - Future projections suggest a potential for growth in specific niches, driven by consumer demand and investment in infrastructure [1]

Core Insights - Critical Infrastructure Technologies Ltd. (CiTech) has commenced steel fabrication for the first three Nexus platforms following a successful Australian Government Grant application [1][4] - Production timelines indicate that Nexus 1 and 2 will be delivered within 10 weeks, while Nexus 3 is expected by the end of January 2026 [2] - The company plans to demonstrate the Nexus platform's capabilities in various sectors including mining, defence, emergency services, and critical infrastructure [2][4] Production and Delivery - Nexus 1 and 2 are expected to arrive at the production facility within 10 weeks, while Nexus 3 will be delivered by the end of January 2026 [2] - After delivery, each platform will undergo final fit-out, with completion anticipated within 4–6 weeks [2] Future Production Plans - Production for Nexus 4 and 5 is set to begin in November 2025, with one unit designated for shipment to Poland for final fit-out [3] - A European product roadshow is planned for March/April 2026 to engage stakeholders in defence, government, and industry across the EU [3] Strategic Engagements - Upcoming demonstrations in Australia will showcase the Nexus platform's versatility and capabilities [2][4] - The platform is designed to provide innovative solutions for sectors such as defence, border security, surveillance, emergency services, and mining [4][5] Company Overview - CiTech is focused on creating autonomous, high-capacity, rapidly deployable technology for essential services [5] - The company's first product, Nexus 16, aims to deliver critical mobile telecommunications solutions [5] - CiTech's self-deploying platform (SDP) addresses limitations of current communication solutions, supporting various technological payloads [5]

Core Insights - Baru Gold Corp. has secured a US$100 million funding partnership with Quantum Metal Thailand, now rebranded as Quantum X Aurum Group (QXA) [2][6] - The partnership aims to advance the Sangihe Gold Project into production, reflecting a long-term collaboration between the two companies [3][4] - QXA has committed to further announcements regarding their partnership with Baru, with no material changes to the existing agreement [5] Company Overview - Baru Gold Corp. is a junior gold developer with NI 43-101 gold resources located in Indonesia, a leading gold-producing country [9] - The Sangihe Gold Project spans approximately 25,000 hectares, with only 10% of the gold-bearing area explored to date [7] - The company holds a 70% interest in the Sangihe mineral tenement Contract of Work (CoW), with a 30-year agreement upon the commencement of production [8]

Core Points - Angkor Resources Corp. is executing shares for debt transactions to settle an aggregate debt of $1,922,800 owed to certain creditors [1][2] - The company plans to issue a total of 8,263,333 Units at a deemed price of $0.21 per Unit, with each Unit consisting of one common share and one-half share purchase warrant [2] - The warrants are exercisable at $0.30 for a period of 24 months and include an acceleration clause if shares trade at $0.40 for 10 consecutive days [2] Debt Settlement Details - The debt settlement includes various components: - Loans totaling $471,300 [4] - A principal payment of $400,000 related to the Evesham acquisition [4] - Amounts due to a 30% participating partner from the Oyadao North license [4] - Notes payable and conversions of $875,000 for the gas capture project in Evesham [5] - Compensation of $62,500 to management and contractors in lieu of cash [5] Management Commentary - The CFO of Angkor expressed satisfaction with the debt settlement, highlighting that it significantly improves the company's balance sheet and reduces interest expenses [6] - The company aims to focus resources on core business initiatives and long-term goals following this transaction [6] Related Party Transactions - The debt conversion involves certain insiders, categorizing it as a "related party transaction" under Multilateral Instrument 61-101 [7] - Angkor may rely on exemptions from formal valuation and minority approval requirements due to the nature of the transaction [8] Closing Conditions - The closing of the Shares for Debt Transaction is subject to customary conditions, including approval from the TSX Venture Exchange [9] - Common Shares issued will be subject to a hold period of four months and one day following issuance [9] Company Overview - Angkor Resources Corp. is a public company listed on the TSX-Venture Exchange, focusing on resource optimization in Cambodia and Canada [10] - The company is involved in carbon capture and gas conservation projects, as well as mineral exploration in Cambodia [10]

 Vancouver, British Columbia – TheNewswire - September 23, 2025 – Nordique Resources Inc. (“Nordique” or the “Company”) (CSE: NORD; OTCQB: NORDF; FSE: V0U) is pleased to provide an update on its ongoing Base-of-Till (BOT) drilling program at the Isoneva Gold Project, located in the emerging Western Finland Gold Belt in Central Finland.Highlights BOT drilling underway: The Phase 1 program, which began in mid August at the high priority Korpisalo target, is progressing well with steady collection of both ti ...

Core Insights - Sernova Biotherapeutics has appointed John L. Brooks III as Chair of the Board of Directors, which is seen as a significant move for the company as it advances its Cell Pouch Bio-hybrid Organ for type 1 diabetes (T1D) treatment [1][2] Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically the Cell Pouch Bio-hybrid Organ, aimed at treating T1D and thyroid disorders [4] - The Cell Pouch integrates human donor cells or stem-cell derived islet-like clusters to create bio-hybrid organs, representing a novel approach to treating chronic diseases [4] Leadership Appointment - John L. Brooks III brings extensive experience in T1D, venture capital, and early-stage company development, which is expected to be invaluable as Sernova progresses in its clinical trials [2][3] - Brooks has a notable background, including serving as Chair and CEO of the Joslin Diabetes Center and co-founding several life science companies, including Insulet Corporation [2][3] Clinical Development - The company is currently advancing its Cell Pouch Bio-hybrid Organ into the final cohort of its ongoing phase 1/2 clinical trial, with the potential to significantly improve islet cell transplantation through novel immunotherapies [2][3]

Core Viewpoint - Gamma Resources Ltd. has engaged Venture Liquidity Providers Inc. to provide market-making services to maintain an orderly trading market for its common shares, subject to TSX Venture Exchange approval [1][2]. Group 1: Market-Making Agreement - The market-making service will be conducted by VLP through W.D. Latimer Co. Ltd., ensuring compliance with TSXV policies and applicable laws [2]. - Gamma has agreed to pay VLP $5,000 per month for its services, with an initial contract term of three months, renewable on a month-to-month basis [3]. - The agreement can be terminated at any time by either Gamma or VLP [3]. Group 2: Relationship and Interests - VLP operates at arm's length from Gamma and has no current interest in the Company or its securities, except for Mr. Cunningham, who holds 135,000 stock purchase options [4]. - The financial resources for the market-making service will be provided exclusively by W.D. Latimer [4]. Group 3: Company Overview - Gamma Resources Ltd. is focused on uranium exploration and development in the U.S., with key projects including the Green River Project in Utah and the Mesa Arc Project in New Mexico [6]. - The Company believes it is well-positioned to benefit from favorable policy and market conditions in the U.S. nuclear sector, aiming to supply responsibly sourced uranium [6].

Core Insights - LAURION Mineral Exploration Inc. has reported promising results from the second set of assay results from its ongoing 7,700-metre drill exploration program at the Ishkoday Project, with approximately 93% of the program completed [1][5] Exploration Results - The second drilling phase evaluated new potential zones west of the Sturgeon River Mine area, including the M24 and M25 vein systems, and tested the continuity of the M1 vein series [2] - Significant assay results include: - LME25-059: 0.50 m grading 16.00 g/t Au and 8.20 g/t Ag from 275.30 m - LME25-058: 0.50 m grading 9.79 g/t Au and 4.80 g/t Ag from 271.75 m - Additional notable grades include 3.13 g/t Au and 23.90 g/t Ag from 189.25 m in LME25-058 [4] - Both drill holes confirmed the presence of multiple narrow, high-grade gold intercepts within broader mineralized envelopes, indicating the potential for stacked high-grade veins [4] Management Commentary - The President and CEO of LAURION highlighted the robust exploration potential of the Ishkoday Project, emphasizing the high-grade gold and silver intercepts and the project's capacity to host multiple mineralized zones [5] Next Steps - The drilling will continue to focus on expanding mineralization within the M-series veins and testing additional strike extensions northeast of the Sturgeon River Mine shaft, with results from remaining drill holes to be released as they become available [6] Assay Turnaround Update - The company has noted that assay laboratories are experiencing increased sample volumes, leading to an extended turnaround time of approximately eight weeks for assay results [11] Company Overview - LAURION is a mid-stage junior mineral exploration and development company focused on the Ishkoday Project, which is 100% owned and covers an area of 57 km², emphasizing gold-rich polymetallic mineralization [14][15]

Company Overview - Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutic areas within the Canadian market [3]. New Appointment - Giovanni Di Genova has been appointed to the Aequus Board of Directors, effective September 12th, 2025, pending completion of his PIF and TSX approval [1][2]. - Doug Janzen, Aequus Chairman & CEO, expressed enthusiasm about working with Giovanni Di Genova on future initiatives [2]. Giovanni Di Genova's Background - Giovanni Di Genova holds a Bachelor of Science and a Bachelor of Pharmacy from McGill University and Université de Montréal, respectively [2]. - He has nearly 35 years of experience in the specialty compounding pharmacy and pharmaceutical industry, covering various therapeutic areas such as ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases [2]. - Di Genova has held multiple roles in both innovative and generic pharmaceutical organizations, with a strong background in strategy, operations, business development, M&A, licensing, co-development, and supply agreements [2].